PNP-rtPA: Biomimetic Nanoparticle Performance Data for Targeted Stroke Thrombolysis

Platelet-membrane-coated nanoparticles conjugated with rtPA (PNP-rtPA) demonstrated enhanced thrombolytic efficacy and safety in mouse models of ischemic stroke. Data from Ziying Feng's 2026 figshare upload includes results from in vitro fibrin clot lysis and in vivo carotid thrombosis and middle cerebral artery occlusion models. The 18.2 KB document likely contains tabular data supporting claims of reduced infarct volume, improved neurological outcomes, and preserved blood-brain barrier integrity.

Use Cases

• Compare thrombolytic efficacy between free rtPA and nanoparticle-conjugated rtPA based on in vitro clot lysis data.
• Evaluate neurovascular safety outcomes based on metrics for blood-brain barrier disruption and hemorrhagic transformation.
• Analyze pharmacokinetic profiles based on circulation time and cerebrovascular accumulation data.
• Assess neurological recovery based on functional outcome scores and survival rates mentioned in the description.

Strengths

• Data is derived from multiple experimental models, including in vitro fibrin clot assays and two distinct in vivo mouse thrombosis models.
• The dataset directly supports a novel biomimetic platform (PNP-rtPA) with clear translational goals for ischemic vascular disease.
• Results include specific outcome measures such as infarct volume reduction, improved cerebral blood flow, and attenuated cytokine release.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (18.2 KB), indicating limited scope, likely summary results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Experimental data from laboratory studies involving biomimetic nanoparticle synthesis and animal models.

Freshness

Last updated 2026-05-11 05:28:41; freshness should be verified.